Showing results (191-200 of 203) with videos related to
Sort By:
Pageof 21
Bioorganic & Medicinal Chemistry Letters|January 16, 2013
Discovery of potent, selective and orally bioavailable imidazo[1,5-a]pyrazine derived ACK1 inhibitorsMeizhong Jin, Jing Wang, Andrew Kleinberg, et al.Bioorganic & Medicinal Chemistry Letters|July 17, 2013
Discovery of 7-aminofuro[2,3-c]pyridine inhibitors of TAK1: optimization of kinase selectivity and pharmacokineticsKeith R Hornberger, Xin Chen, Andrew P Crew, et al.Bioorganic & Medicinal Chemistry Letters|March 5, 2005
Potent and selective [2-imidazol-1-yl-2-(6-alkoxy-naphthalen-2-yl)-1-methyl-ethyl]-dimethyl-amines as retinoic acid metabolic blocking agents (RAMBAs)Mark J Mulvihill, Julie L C Kan, Patricia Beck, et al.Bioorganic & Medicinal Chemistry Letters|November 28, 2006
1,3-Disubstituted-imidazo[1,5-a]pyrazines as insulin-like growth-factor-I receptor (IGF-IR) inhibitorsMark J Mulvihill, Qun-Sheng Ji, Doug Werner, et al.Bioorganic & Medicinal Chemistry Letters|December 17, 2016
Imidazopyridyl compounds as aldosterone synthase inhibitorsBrent R Whitehead, Michael M-C Lo, Amjad Ali, et al.Bioorganic & Medicinal Chemistry|November 7, 2007
Novel 2-phenylquinolin-7-yl-derived imidazo[1,5-a]pyrazines as potent insulin-like growth factor-I receptor (IGF-IR) inhibitorsMark J Mulvihill, Qun-Sheng Ji, Heather R Coate, et al.Bioorganic & Medicinal Chemistry Letters|March 1, 2006
3-[6-(2-Dimethylamino-1-imidazol-1-yl-butyl)-naphthalen-2-yloxy]-2,2-dimethyl-propionic acid as a highly potent and selective retinoic acid metabolic blocking agentMark J Mulvihill, Julie L C Kan, Andrew Cooke, et al.Bioorganic & Medicinal Chemistry Letters|January 12, 2015
Discovery of piperidine ethers as selective orexin receptor antagonists (SORAs) inspired by filorexantIzzat T Raheem, Michael J Breslin, Joseph Bruno, et al.Bioorganic & Medicinal Chemistry Letters|March 1, 2011
Imidazo[1,5-a]pyrazines: orally efficacious inhibitors of mTORC1 and mTORC2Andrew P Crew, Shripad V Bhagwat, Hanqing Dong, et al.Journal of Medicinal Chemistry|July 1, 2008
SAR, pharmacokinetics, safety, and efficacy of glucokinase activating 2-(4-sulfonylphenyl)-N-thiazol-2-ylacetamides: discovery of PSN-GK1Lisa S Bertram, Daniel Black, Paul H Briner, et al.Pageof 21